Volume 59, Issue 5 pp. 553-561
Original Articles: Gastroenterology

Distinctive Colonic Mucosal Cytokine Signature in New-Onset, Untreated Pediatric Crohn Disease

Francisco A. Sylvester

Corresponding Author

Francisco A. Sylvester

Department of Pediatrics, Connecticut Children's Medical Center, Hartford

Address correspondence and reprint requests to Francisco A. Sylvester, MD, Department of Immunology, Connecticut Children's Medical Center, Division of Digestive Diseases, Hepatology and Nutrition, University of Connecticut Health Center, 282 Washington St, Hartford, CT 06106 (e-mail: [email protected]).Search for more papers by this author
Andrew Draghi

Andrew Draghi

Department of Immunology, University of Connecticut Health Center, Farmington

Search for more papers by this author
Antoine Menoret

Antoine Menoret

Department of Immunology, University of Connecticut Health Center, Farmington

Search for more papers by this author
Marina L. Fernandez

Marina L. Fernandez

Department of Pediatrics, Connecticut Children's Medical Center, Hartford

Search for more papers by this author
Zhu Wang

Zhu Wang

Department of Pediatrics, Connecticut Children's Medical Center, Hartford

Search for more papers by this author
Anthony T. Vella

Anthony T. Vella

Department of Immunology, University of Connecticut Health Center, Farmington

Search for more papers by this author
First published: 01 November 2014
Citations: 5

The study was supp orted by Connecticut Children's Medical Center Research Funds and University of Connecticut Health Center Connecticut Institute for Clinical and Translational Science (CICATS).

The authors report no conflicts of interest.

ABSTRACT

Objective:

The aim of the study was to compare the colonic mucosal immune response in children with new, untreated Crohn disease (CD-New), CD in remission (CD-Remission), and unaffected children (CTRL [controls]).

Methods:

We performed flow cytometry of mitogen-stimulated colonic lamina propria mononuclear cells isolated from colonic biopsies and 72-hour biopsy explant cultures, and analyzed the supernatant by an unbiased multiplex cytokine array of 45 analytes.

Results:

Thirty-six children were studied (mean age 14 ± 3 years, 14 girls): 12 CD-New, 11 CD-Remission, and 13 CTRL. We found that stimulation of lamina propria mononuclear cells isolated from colonic biopsies induced comparable intracellular cytokine levels of interferon (IFN-γ), interleukin (IL)-17, and tumor necrosis factor (TNF)-α in T cells from CD-New, CD-Remission, and CTRL, suggesting that mucosal innate inflammation plays a larger role than activated T cells in CD-New. To measure factors released during the ongoing inflammatory response in CD-New, we cultured colonic biopsy explants and uncovered 13/45 factors that were significantly higher in CD-New versus CD-Remission, whereas 10 were increased in CD-New over CTRL. Ingenuity Pathway Analysis software revealed the anticipated interconnectivity of TNF-α, IL-6, and CSF-2 in CD-New of the colon. A novel subnetwork of chemokines was, however, evident, whereas IL-17a appeared as a peripheral factor. Principal component analysis and hierarchal clustering showed that CD-New and CD-Remission separated into distinct subgroups based on the 13 factors.

Conclusions:

At diagnosis of inflammatory bowel disease, the colonic cytokine response contains a predominance of innate immune factors, with chemoattractants and vascular adhesion molecules playing a central role.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.